Table 1.
Drug (s) | Parameter |
Ezetimibe[16] | ↓Visceral fat area |
↓HOMA | |
↓Triglycerides, ↓total cholesterol, ↓LDL-C | |
↓ALT | |
↓hsCRP | |
↓Steatosis grade and NAFLD activity score | |
Ezetimibe plus weight loss[17] | ↓Intrahepatic triglyceride content |
↓hsCRP | |
↓Interleukin-6 | |
↓LDL-C | |
Ezetimibe plus orlistat[20-22] | ↓Body mass index and waist circumference |
↓Total cholesterol and triglycerides | |
↓HOMA | |
↓ALT, AST, γGT |
NAFLD: Non-alcoholic fatty liver disease; HOMA: Homeostasis model assessment; LDL-C: Low density lipoprotein cholesterol; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; γGT: γ-glutamyl-transpeptidase; hsCRP: High sensitivity C-reactive protein.